Zurich, 11 February 2021 – Achiko AG (SWX: ACHI, ISIN CH0522213468) (“Achiko” or the “Company”) held an extraordinary shareholders’ meeting today at 10:00 CET in Zurich. Due to the Covid-19 pandemic, this Extraordinary Shareholders’ Meeting was held without physical presence of the shareholders in accordance with art. 27 para. 1 letter b Covid-19-Ordinance 3. Shareholders exercised their shareholder rights through an independent proxy.
Achiko is pleased to announce that all resolutions were duly passed. A total of 19,578,961 shareholder votes of the total share capital of CHF 1,089,039.00, divided into 108,903,900 registered shares with a nominal value of CHF 0.01 each (of which 105,831,805 are registered in the commercial register and 3,072,095 were issued from conditional capital and are not yet registered in the commercial register), were represented by the independent proxy. The board of directors would like to thank all those who exercised their rights as shareholders in this way.
The shareholders approved to renew the authorized share capital in article 2.2 of the articles of association, authorizing the board of directors to increase the share capital at any time until February 11, 2023 by a maximum amount of CHF 529,159.02 by issuance of a maximum of 52,915,902 registered shares with a par value of CHF 0.01 each, to be fully paid up.
In addition, the shareholders approved to renew the conditional share capital in articles 2.3 and 2.4 of the articles of association under the exclusion of the pre-subscription rights of the shareholders. Article 2.3 for employee participations allows for issuance of up to 19,049,725 fully paid-in registered shares with a par value of CHF 0.01 each, up to an amount of CHF 190,497.25. Article 2.4 for financing, acquisitions and other purposes allows for issuance of up to 33,866,177 fully paid-in registered shares with a par value of CHF 0.01 each, up to an amount of CHF 338,661.77.
“We are grateful to our shareholders and their support”, Allen Wu, Chairman of Achiko said. “The resolutions today give the company the ability to continue with its transformation in delivering a range of relevant services in this pandemic”.
About Achiko AG
We harness ground-breaking science with innovative technology to create solutions that provide a great user experience for patients, physicians and governing bodies alike, leading ultimately to the transformation of the healthcare industry.
The current development of our patent pending diagnostic testing for Covid-19 (Project Gumnuts) provides an easy and effective way that enables people to obtain the information they need and require. Complemented by our mobile check-in app (Teman Sehat), we empower users to manage their diagnostic experiences on their own terms, safeguard their privacy, share experiences, obtain passport verification and find community.
Achiko holds exclusive commercialisation rights to the technology underlying Project Gumnuts from Regenacellx.sl. It may be used to detect all types of Covid-19, but also many other pathogens. Achiko is looking forward to the completion of regulatory approval and getting the technology to market as quickly as possible, applying it in an array of test kits and other assay formats.
Headquartered in Zurich, we have offices in Hong Kong, Jakarta, Singapore and Seoul.
Farner Consulting Ltd.
T: +41 44 266 67 67
Germany and Austria
Axel Mühlhaus / Dr Sönke Knop
T: +49 69 90 55 05-51
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.